Previous 10 | Next 10 |
As of February 2022, more than 100 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy Clinical data updates planned for lead program Zeno in 1H22 and for petosemtamab (“MCLA-158”)...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific...
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against breast cancer, which over the last decade has ...
VANCOUVER – USA News Group – So far in 2022, there have already been some impressive developments in the battle against breast cancer, which over the last decade has been the leading killer of female cancer patients, according to a decade long analysis . In just the fi...
Merus (NASDAQ:MRUS) presents clinical data on zenocutuzumab (Zeno) in combination with trastuzumab and vinorelbine in patients with HER2+ metastatic breast cancer (MBC) at the San Antonio Breast Cancer Symposium in San Antonio, Texas. The primary endpoint of clinical benefit rate (CBR) at 24 ...
- The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met - The triplet combination showed clinically meaningful activity after 3 lines of anti-HER2 therapies including T-DM1 - Validates the potential of zenocutuzumab in additional indication...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific ant...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific ant...
Merus (NASDAQ:MRUS) has priced its offering of 3.86M shares of common stock at $28.50/share, for expected gross proceeds of ~$110.0M. Underwriters' over-allotment is an additional 578,947 shares. All of the shares in the offering are to be sold by Merus. Net proceeds ...
Merus (NASDAQ:MRUS) launched a underwritten public offering of shares; underwriters granted 30-day option to purchase an additional 15% of the shares. Offer size, terms have not yet been disclosed. Net proceeds to be used for advancing the clinical development of its product candida...
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...